Abstract
Background
Following stenting for acute myocardial infarction, transcoronary transplantation of granulocyte‐colony stimulating factor (G‐CSF) mobilized autologous stem cells (ASC) has been shown to result in an increased in‐stent restenosis rate of bare metal stents (BMS).
Hypothesis
This study sought to compare the extent of neointimal growth in BMS and sirolimus‐eluting stents (SES) after primary implantation, and subsequent transcoronary transplantation of G‐CSF mobilized stem cells.
Methods
Patients with stenting of the left anterior descending coronary artery for acute anterior myocardial infarction were randomly assigned to receive a BMS or SES. Intracoronary stem cell injection was performed after G‐CSF application for at least 4 d and cell apheresis. The angiograms obtained after cell transplantation and after 6 mo were analyzed by quantitative coronary angiography.
Results
We performed primary stenting and stem cell transplantion in 16 patients who received a BMS (n = 8) or an SES (n = 8). In 2 patients with a BMS, late stent thrombosis occurred after 58 d and 177 d, respectively. In the remaining patients, control angiography after 6 mo revealed in‐stent restenosis of >50% in no patients with SES but in 4 patients with BMS (67%). Late lumen loss and in‐stent plaque volume were significantly higher in patients with BMS compared with patients with SES.
Conclusions
Compared with BMS, SES impair in‐stent intima hyperplasia after stenting for acute myocardial infarction and transcoronary transplantation of G‐CSF mobilized ASC. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: stem cells, cytokines, in‐stent restenosis, bare metal stents, drug‐eluting stents
Full Text
The Full Text of this article is available as a PDF (94.2 KB).
References
- 1. Kang HJ, Kim HS, Zhang SY, Park KW, Cho HJ, et al.: Effects of intracoronary infusion of peripheral blood stem‐cells mobilised with granulocyte‐colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751–756. [DOI] [PubMed] [Google Scholar]
- 2. Wollert KC, Meyer GP, Lotz J, Ringes‐Lichtenberg S, Lippolt P, et al.: Intracoronary autologous bone‐marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141–148. [DOI] [PubMed] [Google Scholar]
- 3. Schachinger V, Assmus B, Britten MB, Honold J, Lehmann R, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one‐year results of the TOPCARE‐AMI Trial. J Am Coll Cardiol 2004; 44: 1690–1699. [DOI] [PubMed] [Google Scholar]
- 4. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, et al.: Intracoronary injection of CD133 positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction. Circulation 2005; 112: 178–183. [DOI] [PubMed] [Google Scholar]
- 5. Kang HJ, Lee HY, Na SH, Chang SA, Park KW, et al.: Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony‐stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell 3‐DES randomised, controlled trial. Circulation 2006; 114: I145–I151. [DOI] [PubMed] [Google Scholar]
- 6. Steinwender C, Hofmann R, Kammler J, Kypta A, Pichler R, et al.: Effects of peripheral blood stem cell mobilization with granulocyte‐colony stimulating factor and their transcoronary transplantation after primary stent implantation for acute myocardial infarction. Am Heart J 2006; 151: 1296.e7–1296.e13. [DOI] [PubMed] [Google Scholar]
- 7. Cheneau E, Rha SW, Kuchulakanti PK, Stabile E, Kinnaird T, et al.: Impact of sirolimus‐eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty. Catheter Cardiovasc Interv 2005; 65: 469–472. [DOI] [PubMed] [Google Scholar]
- 8. Cho HJ, Kim TY, Cho HJ, Park KW, Zhang SY, et al.: The effect of stem cell mobilization by granulozyte colony stimulating factor on neointimal hyperplasia and endothelial healing after vascular injury with bare metal versus Paclitaxel‐eluting stents. J Am Coll Cardiol 2006; 48: 366–374. [DOI] [PubMed] [Google Scholar]
- 9. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, et al.: Haematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403–409. [DOI] [PubMed] [Google Scholar]
- 10. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, et al.: Pathology of drug‐eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202. [DOI] [PubMed] [Google Scholar]
- 11. Conti CR: Drug‐eluting stents–safety concerns. Clin Cardiol 2006; 29: 479–480. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Newell MC, Henry CR, Sigakis CJ, Unger BT, Larson DM, et al.: Comparison of safety and efficacy of sirolimus eluting stents versus bare metal stents in patients with ST‐elevation myocardial infarction. Am J Cardiol 2006; 97: 1299–1302. [DOI] [PubMed] [Google Scholar]